미숙아 파종혈관내응고에서 Antithrombin Ⅲ 투여의 진단 및 치료적 의의에 대한 연구 = Antithrombin III in the Diagnosis and Treatment of Disseminated Intravascular Coagulation in Premature Infants

다국어 초록 (Multilingual Abstract)

Purpose:We evaluated the diagnostic implications and therapeutic efficacy of antithrombin III(AT III) in the disseminated intravascular coagulation(DIC) of premature infants.
Methods:Ninety-two premature infants diagnosed with DIC and treated with AT III from March, 2000 to May, 2003 were retrospectively reviewed. Clinical manifestations, complete blood counts, coagulation tests, and AT III levels were compared between the two groups:definite DIC if clinical signs of DIC and AT III <70% with more than two abnormal laboratory parameters were present, and suspected DIC if not more than two abnormal laboratory parameters were present.
Results:AT III was given for an average of 3.2 days and no side effects related to the treatment were reported. The AT III levels increased significantly more than four fold with treatment in both groups. The clinical signs and laboratory values improved significantly after treatment.
Conclusion:AT III level is a sensitive parameter in the diagnosis of DIC in premature infants, and it is useful as a treatment modality since it improves the clinical symptoms and the laboratory parameters without significant side effects.

국문 초록 (Abstract)

목 적 : 연자들은 미숙아에서 진단된 파종혈관내응고(DIC)의 임상양상과 혈액응고검사로 antithrombin III(AT III)의 진단적 검사로의 효율성, 투여 전후 검사수치의 변화와 치료 효과를 보고자 하였다. 방 법 : 2000년 3월부터 2003년 5월까지 이화여자대학교 동대문병원과 목동병원 중환아실에 입원하여 DIC로 진단받고 AT III를 투여받았던 미숙아 92명을 대상으로 하였다. 임상증상과 일반혈액검사, 혈액응고검사, AT III 검사소견을 토대로, DIC의 임상 증상이 있고, AT III가 낮으면서 혈소판, PT, aPTT, fibrinogen, FDP, D-dimer 중 3가지 이상에 이상이 있는 환아를 DIC군으로, DIC의 임상 소견과 AT III의 저하는 있으나 혈액검사에서 이상 수치가 2개 이하인 경우를 DIC 의증군으로 나누어서 치료 전후의 검사소견과 임상소견의 호전 여부를 비교분석하였다.

참고문헌 (Reference)

1 "effects of gestational age and prenatal and perinatal events on the coagulation status in premature infants" 88 : 319-323, 2003

2 "Treatment of consumption coagulopathy with antithrombin concentrate in children with acquired antithrombin deficiency - a feasibility pilot study" 158 (158): S187-S191, 1999

3 "Thrombin inhibition is impaired in plasma of sick neonates" 31 : 391-395, 1992

4 "Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation" 15 : 347-352, 1989

5 "The inhibition of blood clotting:An unidentified substance which acts in conjunction with heparin to prevent conversion of prothrombin into thrombin" 125 : 683-687, 1939

6 "The effects of antithrombin III on disseminated intravascular coagulation in premature infants" 22 : 241-245, 1999

7 "Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies" 101 : 816-823, 1992

8 "Neonatal coagulopathy in preterm small-for-gestational-age infants" 83 : 177-181, 2003

9 "High plasma fibrinogen level is associated with poor clinical outcome in DIC patients" 72 : 1-7, 2003

10 "Heparin therapy of diffuse intravascular coagulation" 33 : 105-106, 1975

11 "Hematologic problems in the fetus and neonate. In :Neonatal-Perinatal Medicine" Mosby 1223-1224, 2002

12 "Experience with antithrombin III concentrate in the treatment of disseminated intravascular coagulation" 1 : 185-191, 1994

13 "Effect of delivery modalities on the physiologic inhibition system of coagulation of the neonate" 105 : 15-18, 2002

14 "Effect of antithrombin III in childhood disseminated intravascular coagulopathy" 30 : 69-76, 1995

15 "Do coagulation screening tests detect increased generation of thrombin and plasmin in sick newborn infants" 69 : 418-421, 1993

16 "Disseminated intravascular coagulation; clinical and laboratory aspects" 59 : 65-73, 1998

17 "Disseminated intravascular coagulation syndrome in newborn and childhood" 22 : 5-14, 1979

18 "Disseminated intravascular coagulation and related syndromes:a clinical review" 14 : 299-338, 1988

19 "Disseminated intravascular coagulation : pathophysiology, laboratoy diagnosis and management" 15 : 144-158, 2000

20 "Diagnosis of DIC in very low birth weight infants" 24 : 467-471, 1998

21 "Development of human coagulation system in the full term infant" 70 : 165-172, 1987

22 "Coagulation factors in the premature infant born after about 32 weeks of gestation" 47 : 9-18, 1985

23 "Clinical relevance of antithrombin III" 8 : 276-287, 1982

24 "Clinical experience with antithombin III concentrate in treatment of congenital and acquired deficiency of antithrombin" 87 (87): S53-S60, 19989

25 "Antithrombin inhibits lipopolysaccharide induced tissue factor and interleukin 6 production by mononuclear cells, human umblical vein endothelial cells, and whole" 29 : 134-139, 2001

26 "Antithrombin III:physiology,deficiency,and replacement therapy" 32 : 580-588, 1992

27 "Antithrombin III therapy of dissemianated intravascular coagulation in children" 1 : 98-106, 1994

28 "Antithrombin III patterns in disseminared intravascular coagulation" 73 : 577-583, 1980

29 "Antithrombin III in infancy and childhood" 64 : 624-628, 1975

30 "Antithrombin III concentrates-are they clinically useful?" 73 : 340-348, 1995

31 "An immunoassay for human D-dimer using monoclonal antibodies" 31 : 767-778, 1983

32 "Activation of coagulation system in preterm labor and preterm premature rupture of membranes" 11 : 368-373, 2002

33 "A clinical study of antithrombin III therapy for disseminated intravascular coagulation in neonates" 41 : 593-598, 1998